159 related articles for article (PubMed ID: 30703688)
1. Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods.
Abutayeh RF; Taha MO
J Mol Graph Model; 2019 May; 88():128-151. PubMed ID: 30703688
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods.
Tuffaha GO; Hatmal MM; Taha MO
J Mol Graph Model; 2019 Sep; 91():30-51. PubMed ID: 31158642
[TBL] [Abstract][Full Text] [Related]
3. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors.
Abutayeh RF; Almaliti J; Taha MO
Med Chem; 2020; 16(3):403-412. PubMed ID: 30931863
[TBL] [Abstract][Full Text] [Related]
5. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
Göring S; Bensinger D; Naumann EC; Schmidt B
ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling of JAK1: A target infested with activity-cliffs.
Daoud S; Taha MO
J Mol Graph Model; 2020 Sep; 99():107615. PubMed ID: 32339898
[TBL] [Abstract][Full Text] [Related]
7. Molecular Modeling Studies of
Ghosh S; Keretsu S; Cho SJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors.
Grimm SH; Gagestein B; Keijzer JF; Liu N; Wijdeven RH; Lenselink EB; Tuin AW; van den Nieuwendijk AMCH; van Westen GJP; van Boeckel CAA; Overkleeft HS; Neefjes J; van der Stelt M
Bioorg Med Chem; 2019 Mar; 27(5):692-699. PubMed ID: 30661740
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.
Shahin R; Swellmeen L; Shaheen O; Aboalhaija N; Habash M
J Comput Aided Mol Des; 2016 Jan; 30(1):39-68. PubMed ID: 26685860
[TBL] [Abstract][Full Text] [Related]
10. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
Islam MR; Osman OI; Hassan WMI
J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
12. Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity.
Fernandes ÍA; Braga Resende D; Ramalho TC; Kuca K; da Cunha EFF
Molecules; 2020 Apr; 25(7):. PubMed ID: 32283751
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores.
Al-Sha'er MA; Basheer HA; Taha MO
Mol Divers; 2023 Feb; 27(1):443-462. PubMed ID: 35507210
[TBL] [Abstract][Full Text] [Related]
14. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis.
Al-Sha'er MA; Al-Aqtash RA; Taha MO
Med Chem; 2019; 15(6):588-601. PubMed ID: 30799792
[TBL] [Abstract][Full Text] [Related]
15. Discovering new PI3Kα inhibitors with a strategy of combining ligand-based and structure-based virtual screening.
Yu M; Gu Q; Xu J
J Comput Aided Mol Des; 2018 Feb; 32(2):347-361. PubMed ID: 29306979
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N
Gucký T; Řezníčková E; Radošová Muchová T; Jorda R; Klejová Z; Malínková V; Berka K; Bazgier V; Ajani H; Lepšík M; Divoký V; Kryštof V
J Med Chem; 2018 May; 61(9):3855-3869. PubMed ID: 29672049
[TBL] [Abstract][Full Text] [Related]
18. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.
Frett B; McConnell N; Smith CC; Wang Y; Shah NP; Li HY
Eur J Med Chem; 2015 Apr; 94():123-31. PubMed ID: 25765758
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the structural requirements for designing newer FLT3 inhibitors.
Kar RK; Suryadevara P; Roushan R; Sahoo GC; Dikhit MR; Das P
Med Chem; 2012 Sep; 8(5):913-27. PubMed ID: 22741797
[TBL] [Abstract][Full Text] [Related]
20. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]